Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of VX-121/tezacaftor/deutivacaftor in cystic fibrosis
2021-000713-17Phase 3Active
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vanzacaftor, tezacaftor and deutivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Primary endpoint: Long-term safety and tolerability of VX-121/tezacaftor/deutivacaftor. Started Jul 2022; status: active.
02
Drugs
vanzacaftortezacaftordeutivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2021-000713-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000713-17.